

Table 1 Assumptions affecting the cost-benefit analysis of a national HPV vaccination campaign to prevent cervical cancer in Lebanon

Vaccine-associated costs	Cancer-associated costs
The vaccine provides lifetime protection	The American University of Beirut Medical Center treats the majority of the cervical cancer caseload in Lebanon (in fact just 25%)
Total coverage of all 11-year-old girls	Additional outpatient costs (e.g. transportation fees, traditional treatments and alternative practices) were not included
All cervical cancer cases are caused by HPV and can be avoided by vaccination	Indirect costs of cancer were not included
Only the cost of the vaccine will be considered without additional costs related to personnel and logistics	The additional costs of chemotherapy supplies (solvent, injections, etc.) were not included
The cheaper of the 2 vaccines currently available in Lebanon would be used	Mortality specific data was not available, nor could it be estimated from international data
	Radiotherapy costs were added for all cancers, even when that therapy was not indicated